【 WhatsApp】
+86-21-6420 0566
8618501763615
| OEM | OEM Services Provided |
| Feature | Good stability,Easy to Use |
| Classification | Catalysts and Additives |
| Advantage | Professional, Fast Delivery, Customizable | Samples | Apply for free，Contact us now. |
| Common Name | Oleoylethanolamide | ||
|---|---|---|---|
| CAS Number | 111-58-0 | Molecular Weight | 325.529 |
| Density | 0.9±0.1 g/cm3 | Boiling Point | 496.4±38.0 °C at 760 mmHg |
| Molecular Formula | C20H39NO2 | Melting Point | 50-60ºC |
| MSDS | ChineseUSA | Flash Point | 254.0±26.8 °C |
| Symbol | GHS07 | Signal Word | Warning |
| Name | oleoyl ethanolamide |
|---|---|
| Synonym | More Synonyms |
| Description | Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis. |
|---|---|
| Related Catalog | Natural Products >>OthersResearch Areas >>Cardiovascular DiseaseResearch Areas >>Metabolic Disease |
| Target | Human Endogenous Metabolite PPAR-α |
| In Vitro | Oleoylethanolamide (OEA), an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oleoylethanolamide suppresses TGF-β1 induced hepatic stellate cells (HSCs) activation in vitro via PPAR-α. To assess the impact of Oleoylethanolamide on HSCs activation, the expression levels of α-SMA and Col1a in TGF-β1-stimulated HSCs are examined by qPCR. The mRNA levels of α-SMA and Col1a are markedly induced in the group of CFSC cells with TGF-β1 (5 ng/mL) stimulation for 48h, while the mRNA levels are suppressed when treated with Oleoylethanolamide in a dose-dependent manner. Immunofluorescence and western blot results show that Oleoylethanolamide treatment dose-dependently inhibits the protein expression of α-SMA, the marker of HSC activation. The inhibitory effects of Oleoylethanolamide on HSCs activation are completely blocked by PPAR-α antagonist MK886 (10 μM). Moreover, the mRNA and protein expression levels of PPAR-α are down-regulated with TGF-β1 stimulation, while Oleoylethanolamide treatment restores these changes in dose-dependent manner. In addition, the phosphorylation of Smad 2/3 is upregulated in the presence of TGF-β1 stimulation, consistent with the observed effects on HSC activation, while Oleoylethanolamide (10 μM) reduces the phosphorylation of Smad2/3 in CFSC simulated with TGF-β1[1]. |
| In Vivo | Oleoylethanolamide (OEA) can significantly suppress the pro-fibrotic cytokine TGF-β1 negatively regulate genes in the TGF-β1 signaling pathway (α-SMA, collagen 1a, and collagen 3a) in mice models of hepatic fibrosis. Treatment with Oleoylethanolamide (5 mg/kg/day, intraperitoneal injection, i.p.) significantly attenuates the progress of liver fibrosis in both two experimental animal models by blocking the activation of hepatic stellate cells (HSCs)[1]. |
| Cell Assay | CFSC, HSC cell lines are first obtained from cirrhotic rat liver, and have a similar phenotype to that of early passage primary HSCs. CFSC cells are cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. All cells are cultured in 6-well culture plates under 37°C and 5% CO2 in an incubator. The medium is replaced every two days, and the cells are harvested and diluted at a ratio of 1:3 twice a week. In experiments, HSCs are pretreated with the experimental concentration of Oleoylethanolamide (30 μM, 10 μM, 3 μM) before stimulation with 5 ng/mL TGF-β1. mRNA expression levels of α-SMA (A) and Col1a (B) are analyzed by real-time PCR[1]. |
| Animal Admin | Mice[1] The Sv/129 mice and PPAR-α knockout mice are maintained in a room with controlled temperature (21-23°C), humidity (55-60%) and lighting (12 h light/dark cycles) and given water ad libitum. Mice are randomly divided for methionine choline-deficient (MCD) and thioacetamide (TAA) experiments. In the MCD-diet feeding experiment, wild-type Sv/129 mice and PPAR-α knockout mice are each divided into three groups (n=8 /group): (i) control group receive normal diet; (ii) fed with MCD diet and injected with the vehicle (5% Tween-80+5% PEG400+90% saline, 5 mL/kg/day, 8 weeks, intraperitoneal injection, i.p.); (iii) fed with MCD diet along with Oleoylethanolamide administration (5 mg/kg/day; 8 weeks, i.p.). In another set of experiment, all the wild-type mice and PPAR-α knockout mice are given standard chow diet, and are randomly separated into three groups: the control group is not administrated TAA or Oleoylethanolamide but is injected with the saline; the TAA group is injected with TAA (160 mg/kg, three times per week, 6 weeks, dissolved in saline, i.p.) plus the corresponding vehicle; the Oleoylethanolamide group is both injected with TAA and Oleoylethanolamide (5 mg/kg/day; 6 weeks, i.p.)[1]. |
| References | [1]. Chen L, et al. Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oncotarget. 2015 Dec 15;6(40):42530-40 |
| Density | 0.9±0.1 g/cm3 |
|---|---|
| Boiling Point | 496.4±38.0 °C at 760 mmHg |
| Melting Point | 50-60ºC |
| Molecular Formula | C20H39NO2 |
| Molecular Weight | 325.529 |
| Flash Point | 254.0±26.8 °C |
| Exact Mass | 325.298065 |
| PSA | 49.33000 |
| LogP | 6.36 |
| Vapour Pressure | 0.0±2.9 mmHg at 25°C |
| Index of Refraction | 1.474 |
| InChIKey | BOWVQLFMWHZBEF-KTKRTIGZSA-N |
| SMILES | CCCCCCCC/C=CCCCCCCCC(=O)NCCO |
| Storage condition | −20°C |
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi:Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Neurobiol. Dis. 74 , 295-304, (2015) Long-term administration of l-3,4-dihydroxyphenylalanine (levodopa), the mainstay treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of action and motor complicatio... | |
| The human serum metabolome. PLoS ONE 6(2) , e16957, (2011) Continuing improvements in analytical technology along with an increased interest in performing comprehensive, quantitative metabolic profiling, is leading to increased interest pressures within the m... | |
| A simple method for simultaneous determination of N-arachidonoylethanolamine, N-oleoylethanolamine, N-palmitoylethanolamine and 2-arachidonoylglycerol in human cells. Anal. Bioanal. Chem 407(6) , 1781-7, (2015) The endocannabinoid system has been considered as a target for pharmacological intervention. Accordingly, inhibition of fatty acid amide hydrolase (FAAH), a degrading enzyme of the endocannabinoids N-... |
| Oleic acid ethanolamide |
| 9-Octadecenamide, N-(2-hydroxyethyl)-, (9Z)- |
| MFCD08059579 |
| N-(2-Hydroxyethyl)oleamide |
| N-(Hydroxyethyl)oleamide N-(cis-9-Octadecenoyl)ethanolamine OEA oleoylethanolamide |
| N-(9Z-octadecenoyl)-ethanolamine |
| Oleoyl monoethanolamide |
| (9Z)-N-(2-hydroxyethyl)octadec-9-enamide |
| N-oleoyl ethanolamide |
| Oleoylethanolamide |
| N-Oleoylethanolamine |
| 9-Octadecenamide, N-(2-hydroxyethyl)-, (Z)- |
| N-Oleoyl-2-aminoethanol |
| (9Z)-N-(2-Hydroxyethyl)-9-octadecenamide |
| N-(cis-9-Octadecenoyl)ethanolamine |
| N-oleoyl ethanolamine |
| Oleic acid monoethanolamide |
| EINECS 203-884-8 |
| 9Z-octadecenoylethanolamide |
| Oleoyl Ethanolamide |
Declaration: The products displayed on this website are intended exclusively for industrial applications or scientific research. They are not intended for medical, pharmaceutical, or food use. In accordance with applicable laws and regulations, purchasing organizations must hold valid qualifications and approvals.
Ready to Start?
For help with solutions customized to your business needs, contact Export Director now.
With 30+ years of experience and We firmly believe that product quality is the basis of cooperation.
Chat Now
Phone
8618501763615
Working hours
Monday to Friday
TEl
+86-21-6420 0566
